The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trial

Ronald de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, C Schmidt, JK Evans, KJ Horgan

Research output: Contribution to journalArticleAcademicpeer-review

153 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)403-410
Number of pages8
JournalEuropean Journal of Cancer
Publication statusPublished - 2004

Cite this